The End Price Gouging for Medications Act establishes annual reference prices for prescription drugs based on the lowest retail prices in 12 international reference countries (like Canada and the UK) or specific criteria if international data is unavailable. It requires drug manufacturers to sell medications at or below these reference prices for all patients covered by federal health programs - including Medicare, Medicaid, TRICARE, and VA care - as well as for all other patients, including those with private insurance. Manufacturers violating this rule face civil penalties of five times the revenue difference, with collected funds directed to the National Institutes of Health for drug research. This bill directly affects drug manufacturers and millions of Americans enrolled in the specified federal health programs.
This bill requires Medicare to cover lung cancer biomarker testing for beneficiaries diagnosed with lung cancer, starting January 1, 2027. It defines the testing as procedures analyzing tissue, blood, or bodily fluids to identify specific biomarkers (like genes or proteins) for treatment planning. Medicare will pay 100% of reasonable charges for these tests, removing out-of-pocket costs for patients. The policy directly affects Medicare patients with lung cancer who need this specialized testing to guide personalized treatment options.
The Health Investment Zones Act of 2026 creates a program to designate areas with significant health disparities as "Health Investment Zones" to improve health outcomes. The bill provides tax incentives including a new 30% tax credit for wages paid to qualified Health Investment Zone workers and incentive payments for Medicare services provided in these zones. It also establishes a grant program for community organizations to fund health care improvements and a student loan repayment program for health care practitioners working in designated zones. Areas must meet specific criteria related to income levels, health outcomes, and documented health disparities to qualify for designation, with zones designated for 10 years.
The Medicare for All Act would establish a government-run health insurance program providing comprehensive coverage to all U.S. residents, replacing current private insurance, Medicare, and Medicaid. The program would cover all medically necessary services including hospital care, prescription drugs, dental, vision, mental health, and reproductive care without patient cost-sharing (except for limited prescription drug cost-sharing under specific conditions). It would prohibit private insurers from selling duplicate coverage and require employers to stop providing duplicate benefits, while allowing supplemental coverage for additional services not included in the core benefits package. The bill includes a transition period with immediate coverage for children and a gradual phase-in for full implementation, with benefits first available for most individuals in 2027. The program would be funded through a new Medicare for All Trust Fund, consolidating current health care program revenues.
This bill requires the Health and Human Services Secretary to create a process by January 1, 2026, allowing specific healthcare research groups (qualified clinical data registries and clinician-led registries) to access Medicare claims data, and potentially Medicaid/CHIP data if approved. These groups can link claims data with clinical outcomes to assess provider quality, improve patient safety, and conduct research. The data will be provided at cost (covering only the fee to make it available), with fees deposited into the CMS account. It directly affects healthcare researchers and providers by enabling data-driven quality improvement efforts.
This bill amends the Congressional Budget Act to explicitly prohibit changes to Medicare and Medicaid through the budget reconciliation process. It modifies Section 310(g) to add specific references to Medicare (Title XVIII) and Medicaid (Title XIX) of the Social Security Act, ensuring these programs are excluded from reconciliation considerations. The key mechanism prevents Congress from using the fast-track budget reconciliation procedure to alter Medicare or Medicaid funding, benefits, or structure. This directly affects congressional budget procedures, not the programs themselves, by restricting how lawmakers can make changes to these healthcare programs.
This bill extends Medicare payment incentives for healthcare providers using alternative payment models, directly affecting Medicare participating doctors and hospitals. It updates specific years in payment formulas from 2026 to 2027 and adjusts the 2027 incentive rate from 1.88% to 3.53%. The key mechanism modifies Medicare payment rules to maintain existing financial incentives through 2028, ensuring continuity for providers participating in these models. The changes are technical amendments to the Social Security Act's Medicare provisions.
The Telehealth Modernization Act extends key Medicare telehealth flexibilities through 2027, removing geographic restrictions and allowing audio-only visits. It expands who can provide telehealth services (including nurse practitioners and rural health clinics) and requires new guidance for serving patients with limited English proficiency. The bill also extends certain hospice care provisions and includes virtual diabetes prevention program options. These changes directly affect Medicare beneficiaries, healthcare providers, and telehealth technology companies.
SRES 324 is a non-binding Senate resolution expressing concern over actions taken by the Trump Administration. It criticizes policies that drastically reduced federal agency staff, froze critical funding, and dismantled agencies, stating these actions harm communities and raise costs for families. The resolution specifically highlights impacts on programs serving 32 million patients through health centers, Social Security/Medicare access, veterans' services, small business support, and medical research. It does not create new policy but formally states the Senate’s view that these actions are destructive and harmful. The resolution lists 12 specific areas affected, including housing assistance, disability education programs, and foreign aid reductions.
HRES 657 is a non-binding House resolution affirming that the retirement age for Social Security and Medicare should not be raised, referencing President Trump’s 2024 pledge. It states the House’s position that current eligibility ages must be preserved, rejecting proposals to delay access to benefits for seniors. The resolution highlights that raising retirement ages would disproportionately impact workers in physically demanding jobs and lower-income communities who rely on these programs for income and healthcare. As a symbolic statement - not a law - it expresses support for maintaining existing benefits but does not change policy or create new obligations.